Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-KLK2 Antibody (R3F53)

Catalog #:   RHD37701 Specific References (12) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: ELISA, FCM, IF, IHC
Accession: P20151
Overview

Catalog No.

RHD37701

Species reactivity

Human

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400, IF: 1:50-1:200, IHC: 1:200-1:1000

Target

Kallikrein-2, Tissue kallikrein-2, KLK2, hGK-1, Glandular kallikrein-1

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P20151

Applications

ELISA, FCM, IF, IHC

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3F53

Data Image
  • Flow Cytometry
    Flow cytometric analysis of LNCAP cells using KLK2 mouse mAb (green) and negative control (red).
  • Immunofluorescence
    Immunofluorescence analysis of Hela cells using KLK2 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human prostate cancer tissues using KLK2 mouse mAb with DAB staining.
References

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study., PMID:40450573

Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies., PMID:39272956

A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer., PMID:38782459

Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2., PMID:38396898

Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy., PMID:32532924

Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence., PMID:31741711

Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer., PMID:29691406

Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6., PMID:26116115

Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome., PMID:25649018

Tickling stimulation causes the up-regulation of the kallikrein family in the submandibular gland of the rat., PMID:22982067

Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies., PMID:20615888

Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate-specific antigen., PMID:9140120

Datasheet

Document Download

Anti-KLK2 Antibody (R3F53).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-KLK2 Antibody (R3F53) [RHD37701]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only